Capricor Therapeutics Class Action: Important Info for Investors Facing Losses
In a recent announcement, Robbins LLP has called attention to a class action lawsuit involving Capricor Therapeutics, Inc. This comes as a significant opportunity for shareholders who have faced considerable losses on their investments in the biotechnology company. Capricor, traded on NASDAQ under the ticker CAPR, specializes in developing innovative cell and exosome-based therapies, with a primary focus on Duchenne muscular dystrophy (DMD). During the time frame from October 9, 2024, to July 10, 2025, investors who acquired Capricor securities may have been misled about the viability of their lead therapeutic candidate, deramiocel. This drug was aimed at treating cardiomyopathy associated with DMD.
The allegations against Capricor state that the company misrepresented key facts concerning the safety and efficacy of deramiocel, which was under review by the FDA. During the class period, Capricor executives gave shareholders the false impression that they were on the brink of receiving approval to market their drug. However, it has since been revealed that Capricor concealed important data from its Phase 2 HOPE-2 clinical trial, which raised serious questions about deramiocel’s effectiveness and safety profile.
The situation escalated when Capricor announced on July 11, 2025, that the FDA had issued a Complete Response Letter (CRL). This letter explicitly stated that Capricor's application failed to meet the regulatory requirements for substantial evidence demonstrating effectiveness, thus necessitating additional clinical data before any further consideration. Following this disclosure, Capricor's stock plummeted, dropping from $11.40 to $7.64 in mere days, significantly impacting investors who had purchased shares at inflated prices based on misleading information.
Given these developments, shareholders are encouraged to evaluate their options. If you believe you have been adversely affected by Capricor’s misleading statements and wish to participate in the class action lawsuit, Robbins LLP invites you to reach out. You can express your interest in acting as a lead plaintiff, a role essential for guiding the litigation process on behalf of other impacted investors. However, it’s important to note that participation in the case is not a prerequisite for potential recovery; those preferring to remain absent can still benefit from any outcomes reached through the class action.
Robbins LLP operates on a contingency fee basis, meaning shareholders will incur no upfront fees or legal expenses throughout this legal procedure. The firm has established itself as a leading entity in shareholder rights litigation, advocating for the recovery of losses, enhancing corporate governance, and holding executives responsible for their conduct since its inception in 2002.
Investors interested in being notified about updates on the Capricor class action or wanting to receive alerts regarding corporate misconduct are encouraged to enroll in the firm's Stock Watch service. Through this service, Robbins LLP provides timely updates and critical information to its clients, empowering them to remain informed of their rights as shareholders.
In conclusion, this class action represents a vital opportunity for Capricor investors to seek justice and potentially recover their losses. Don’t miss out on this important chance—reach out to Robbins LLP today for further information on how to proceed with your claim.
The allegations against Capricor state that the company misrepresented key facts concerning the safety and efficacy of deramiocel, which was under review by the FDA. During the class period, Capricor executives gave shareholders the false impression that they were on the brink of receiving approval to market their drug. However, it has since been revealed that Capricor concealed important data from its Phase 2 HOPE-2 clinical trial, which raised serious questions about deramiocel’s effectiveness and safety profile.
The situation escalated when Capricor announced on July 11, 2025, that the FDA had issued a Complete Response Letter (CRL). This letter explicitly stated that Capricor's application failed to meet the regulatory requirements for substantial evidence demonstrating effectiveness, thus necessitating additional clinical data before any further consideration. Following this disclosure, Capricor's stock plummeted, dropping from $11.40 to $7.64 in mere days, significantly impacting investors who had purchased shares at inflated prices based on misleading information.
Given these developments, shareholders are encouraged to evaluate their options. If you believe you have been adversely affected by Capricor’s misleading statements and wish to participate in the class action lawsuit, Robbins LLP invites you to reach out. You can express your interest in acting as a lead plaintiff, a role essential for guiding the litigation process on behalf of other impacted investors. However, it’s important to note that participation in the case is not a prerequisite for potential recovery; those preferring to remain absent can still benefit from any outcomes reached through the class action.
Robbins LLP operates on a contingency fee basis, meaning shareholders will incur no upfront fees or legal expenses throughout this legal procedure. The firm has established itself as a leading entity in shareholder rights litigation, advocating for the recovery of losses, enhancing corporate governance, and holding executives responsible for their conduct since its inception in 2002.
Investors interested in being notified about updates on the Capricor class action or wanting to receive alerts regarding corporate misconduct are encouraged to enroll in the firm's Stock Watch service. Through this service, Robbins LLP provides timely updates and critical information to its clients, empowering them to remain informed of their rights as shareholders.
In conclusion, this class action represents a vital opportunity for Capricor investors to seek justice and potentially recover their losses. Don’t miss out on this important chance—reach out to Robbins LLP today for further information on how to proceed with your claim.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.